Munich, Germany

Marc Sedlaczek

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Arthrex, Gmbh. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Marc Sedlaczek: Innovator in Meniscal Allograft Transplantation

Introduction

Marc Sedlaczek is a notable inventor based in Munich, Germany. He has made significant contributions to the field of medical technology, particularly in the area of meniscal allograft transplantation. His innovative work has the potential to improve patient outcomes in orthopedic surgery.

Latest Patents

Marc Sedlaczek holds a patent for a meniscal allograft transplantation system and methods for use. This patent outlines a system designed to enhance the transplantation process of meniscal allografts, providing a more effective solution for patients requiring this type of surgery. He has 1 patent to his name, showcasing his expertise and commitment to advancing medical technology.

Career Highlights

Marc is currently employed at Arthrex GmbH, a company known for its dedication to developing innovative surgical solutions. His role at Arthrex allows him to work on cutting-edge technologies that aim to improve surgical procedures and patient care.

Collaborations

Marc collaborates with various professionals in the field, including his coworker Bryan Cannon. Their combined expertise contributes to the development of advanced medical solutions that benefit both surgeons and patients.

Conclusion

Marc Sedlaczek is a prominent figure in the field of medical innovation, particularly in meniscal allograft transplantation. His contributions through patents and collaboration with industry professionals highlight his commitment to improving surgical techniques and patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…